NFATc2 is a potential therapeutic target in human melanoma

Journal of Investigative Dermatology

Volumn 132, Issue 11, 2012, Pages 2652-2660

  Perotti, Valentina ^a   Baldassari, Paola ^a   Bersani, Ilaria ^a   Molla, Alessandra ^a   Vegetti, Claudia ^a   Tassi, Elena ^a   Col, Jessica Dal ^b   Dolcetti, Riccardo ^b   Anichini, Andrea ^b   Mortarini, Roberta ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CASPASE; CYCLOSPORIN A; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NUCLEAR FACTOR OF ACTIVATED T CELLS C2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84867847305     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.179     Document Type: Article

References (39)

1. Allen DH, Lepple-Wienhues A, Cahalan MD (1997) Ion channels phenotype of human melanoma cells. J Membr Biol 155:27-34 (Pubitemid 27046529)
2. Anichini A, Mortarini R, Nonaka D et al. (2006) Association of antigenprocessing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405-11
3. Caballero FJ, Navarrete CM, Hess S et al. (2007) The acetaminophen- derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol 73:1013-23 (Pubitemid 46283579)
4. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
5. Ciechomska I, Legat M, Golab J et al. (2005) Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. Int J Cancer 117:59-67 (Pubitemid 41262760)
6. Daniotti M, Oggionni M, Ranzani T et al. (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968-77 (Pubitemid 39093541)
7. Deli T, Varga N, Adam A et al. (2007) Functional genomics of calcium channels in human melanoma cells. Int J Cancer 121:55-65 (Pubitemid 46753851)
8. Eckstein LA, Van Quill KR, Bui SK et al. (2005) Cyclosporin A inhibits calcineurin/nuclear factor of activated T- cells signaling and induces apoptosis in retinoblastoma cells. IOVS 46:782-90 (Pubitemid 41321012)
9. Eton O, Legha SS, Bedikian AY et al. (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045-52 (Pubitemid 34408794)
10. Feun L, Marini A, Moffat F et al. (2005) Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer Invest 23:3-8 (Pubitemid 40344193)
11. Garbe C, Eigentler TK, Keiholz U et al. (2011) Systematic review of medical treatment in melanoma: current status and future prospects. The Oncologist 16:5-24
12. Gregory MA, Phang TL, Neviani P et al. (2010) Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18:74-87
13. Guha M, Xia F, Raskett CM et al. (2010) Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene 29:1280-92
14. Han X, Yoon SH, Ding Y et al. (2010) Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep 23:1053-62
15. Hocker TL, Singh MK, Tsao H (2008) Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128:2575-95
16. Ito C, Ribeiro RC, Behm FC et al. (1998) Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91:1001-7 (Pubitemid 28078304)
17. Köenig A, Linhart T, Schlengemann K et al. (2010) NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 138:1189-99
18. Kumar S (2009) Caspase 2 in apoptosis, the DNA damage response and tumor suppression: enigma no more? Nat Rev Cancer 9:897-903
19. Lockart RJ, Armstrong JL, Reynolds NJ et al. (2009) NFAT signaling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer 101:1448-55
20. Lopergolo A, Pennati M, Gandellini P et al. (2009) Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Br J Cancer 100:739-46
21. Luo C, Burgeon E, Carew JA et al. (1996) Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. Mol Cell Biol 16:3955-66 (Pubitemid 26199915)
22. Mancini M, Toker A (2009) NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9:810-20
23. Mann JR, Backlund MG, DuBois RN (2005) Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2:202-10 (Pubitemid 40812470)
24. Manzl C, Krumschnabel G, Bock F et al. (2009) Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol 185:291-303
25. Medyouf H, Ghysadel J (2008) The calcineurin/NFAT signaling pathway. A novel therapeutic target in leukemia and solid tumors. Cell Cycle 7:1-7
26. Mortarini R, Vegetti C, Molla A et al. (2009) Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 15:4085-94
27. Parham P, Barnstable CJ, Bodmer WF (1979) Use of monoclonal antibody (W6/32) in structural studies of HLA-A, -B, -C antigens. J Immunol 123:536-45
28. Petti C, Molla A, Vegetti C et al. (2006) Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 66:6503-11 (Pubitemid 44085604)
29. Poulikakos PI, Rosen N (2011) Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19:11-5
30. Pu WT, Ma Q, Izumo S (2003) NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 92:725-31 (Pubitemid 36457636)
31. Ren J, Shi M, Liu R et al. (2005) The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci USA 102:565-70 (Pubitemid 40282705)
32. Sato M, Tsujino I, Fukunaga M et al. (2011) Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway. Anticancer Res 31:2129-34
33. Sensi M, Nicolini G, Petti C et al. (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single cell level in the same human melanoma. Oncogene 25:3357-64 (Pubitemid 43877040)
34. Singh G, Singh SV, Konig A et al. (2010) Sequential activation of NFAT and c- Myc transcription factors mediates the TGF-b switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 285:27241-50
35. Sohn D, Budach W, Janicke RU (2011) Caspase-2 is required for DNA damage-induced expression of the CDK inhibitor p21WAF1/CIP1. Cell Death Differ 18:1664-74
36. Soleimanpour SA, Crutchlow MF, Ferrari AM et al. (2010) Calcineurin signaling regulates human islet b-cell survival. J Biol Chem 285: 40050-9
37. Weigmann B, Lehr HA, Yancopoulos G et al. (2008) The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 205:2099-110
38. Wu W, Misra RS, Russell JQ et al. (2006) Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3. J Biol Chem 281:10682-90 (Pubitemid 43855489)
39. Zanon M, Piris A, Bersani I et al. (2004) Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 64:7386-94 (Pubitemid 39372078)